Clinical Trials in Watertown, Massachusetts

29 recruiting

Showing 120 of 29 trials

Recruiting
Phase 3

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

Depressive Disorder, Major
Janssen Research & Development, LLC752 enrolled205 locationsNCT06559306
Recruiting

A Study to Evaluate Sleep Electroencephalogram (EEG) Features (Brain Activity While Sleeping) in Participants With Major Depressive Disorder (MDD)

Depressive Disorder, Major
Janssen Research & Development, LLC80 enrolled23 locationsNCT07258485
Recruiting
Phase 2

A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)

Treatment Resistant Depression
atai Therapeutics, Inc.142 enrolled48 locationsNCT06524830
Recruiting
Phase 2

Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

Alzheimer DiseaseAlzheimer Disease Due to P. Gingivalis
Lighthouse Pharmaceuticals, Inc.300 enrolled35 locationsNCT06847321
Recruiting
Phase 3

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

Alzheimers Disease
Hoffmann-La Roche13,000 enrolled211 locationsNCT07177352
Recruiting
Phase 2

A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression

Major Depressive Disorder (MDD)
Draig Therapeutics Ltd300 enrolled40 locationsNCT07300969
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

Alzheimer s Disease
Bristol-Myers Squibb586 enrolled123 locationsNCT06976203
Recruiting
Phase 2

A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)

Bipolar Disorder
Eli Lilly and Company400 enrolled88 locationsNCT07286175
Recruiting
Phase 2

A Study of Brenipatide in Participants With Opioid Use Disorder

Opioid-use Disorder
Eli Lilly and Company465 enrolled57 locationsNCT07420283
Recruiting
Phase 3

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Major Depressive Disorder
Neurocrine Biosciences850 enrolled87 locationsNCT06966401
Recruiting
Phase 2

A Study of Brenipatide in Adult Participants With Schizophrenia

Schizophrenia
Eli Lilly and Company450 enrolled102 locationsNCT07410507
Recruiting
Phase 3

NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

Schizophrenia
Neurocrine Biosciences800 enrolled53 locationsNCT07114874
Recruiting
Phase 3

A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

Alzheimers Disease
Hoffmann-La Roche800 enrolled146 locationsNCT07170150
Recruiting
Phase 3

Study to Assess the Safety and Effectiveness of NMRA-335140-501

Major Depressive Disorder
Neumora Therapeutics, Inc.1,000 enrolled178 locationsNCT06029439
Recruiting
Phase 3

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)

Major Depressive Disorder
Xenon Pharmaceuticals Inc.450 enrolled42 locationsNCT07076407
Recruiting
Phase 3

A Study of Brenipatide in Adult Participants With Major Depressive Disorder

Depressive Disorder, Major
Eli Lilly and Company1,000 enrolled186 locationsNCT07412756
Recruiting
Phase 3

A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults

Chronic Idiopathic Constipation (CIC)
Ardelyx692 enrolled79 locationsNCT07382167
Recruiting
Phase 3

Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder

Major Depressive Disorder
Neumora Therapeutics, Inc.332 enrolled74 locationsNCT06058013
Recruiting
Phase 3

NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

Schizophrenia
Neurocrine Biosciences284 enrolled21 locationsNCT06963034
Recruiting
Phase 3

A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)

Generalized Anxiety Disorder
Definium Therapeutics US, Inc.200 enrolled36 locationsNCT06741228